Table 1.
Baseline characteristics of the study population.
| Rejection group (n=17) | Rejection within 1 year of IS reduction (n=4) | No rejection group (n=62) | P-value* | P-value** | |
|---|---|---|---|---|---|
| Gender (male) | 12 (70.6%) | 4 (100%) | 32 (51.6%) | 0.182 | 0.120 |
| Age (years) | 44.12±12.01 | 44.75±12.42 | 45.10±10.85 | 0.748 | 0.887 |
| Body mass index (kg/m2) | 24.13±3.92 | 26.77±4.28 | 22.40±3.31 | 0.070 | 0.036 |
| Medical history | |||||
| Diabetes mellitus | 2 (11.8%) | 0 (0%) | 11 (17.7%) | 0.723 | 1.000 |
| Hypertension | 15 (88.2%) | 4 (100%) | 54 (87.1%) | 1.000 | 1.000 |
| Cardiovascular disease | 1 (5.9%) | 0 (0%) | 4 (6.5%) | 1.000 | 1.000 |
| Hepatitis B virus | 0 (0%) | 0 (0%) | 5 (8.1%) | 0.579 | 1.000 |
| Dialysis (non-preemptive) | 15 (88.2%) | 15 (88.2%) | 55 (88.7%) | 1.000 | 1.000 |
| Hemodialysis | 11 (73.3%) | 3 (75.0%) | 47 (85.5%) | 0.271 | 1.000 |
| Duration (months) | 38.53±44.50 | 11.67±15.95 | 52.29±60.02 | 0.412 | 0.128 |
| Living-donor KT | 14 (82.4%) | 4 (100%) | 42 (67.7%) | 0.367 | 0.306 |
| Delayed graft function | 2 (11.8%) | 0 (0%) | 4 (6.5%) | 0.604 | 1.000 |
| Number of KT | |||||
| ≥2 times | 1 (5.9%) | 0 (0%) | 7 (11.3%) | 1.000 | 1.000 |
| ABO-incompatible KT | 0 (0%) | 0 (0%) | 10 (16.1%) | 0.108 | 1.000 |
| HLA-sensitized KT | 2 (11.8%) | 2 (50.0%) | 6 (9.7%) | 1.000 | 0.069 |
| HLA mismatches | |||||
| ≥4 mismatches | 7 (41.2%) | 3 (75.0%) | 26 (41.9%) | 1.000 | 0.312 |
| PRA ≥10% | 1 (5.9%) | 0 (0%) | 10 (16.1%) | 0.440 | 1.000 |
| Donor gender (male) | 6 (35.3%) | 0 (0%) | 35 (56.5%) | 0.172 | 0.044 |
| Donor age (years) | 41.24±8.63 | 42.25±9.43 | 45.87±11.32 | 0.121 | 0.397 |
| F/U duration (months) | 75.41±18.33 | 71.50±12.40 | 73.76±15.60 | 0.710 | 0.650 |
| First-detected BKV PCR (log copy/ml) | 4.48±1.30 | 4.46±0.32 | 4.53±1.00 | 0.842 | 0.866 |
| Peak BKV PCR (log copy/ml) | 4.96±1.16 | 4.74±0.39 | 5.17±0.90 | 0.427 | 0.491 |
BKV – BK virus; F/U – follow-up; HLA – human leukocyte antigen; IS – immunosuppression; KT – kidney transplantation; PRA – panel reactive antibody.
*
P-value – rejection group vs. no rejection group;
**
P-value – rejection group within 1 year vs. no rejection group.